Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models

Japanese Journal of Pharmacology

Volumn 79, Issue 4, 1999, Pages 477-483

  Waki, Yoshihiro ^a,b   Horita, Takashi ^b   Miyamoto, Ken ichi ^b   Ohya, Keiichi ^a   Kasugai, Shohei ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Inhibitor; Ovariectomized rat; Phosphodiesterase 4; Sciatic neurectomized rat; Walker256 carcinosarcoma

Indexed keywords

1 BUTYL 3 PROPYLXANTHINE; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MARROW CULTURE; BONE MINERAL; BONE MINERALIZATION; CARCINOSARCOMA; CELL CULTURE; CONTROLLED STUDY; FEMALE; NEURECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OVARIECTOMY; RAT; SCIATIC NERVE;

EID: 0032960558     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.79.477     Document Type: Article

References (43)

1. Christiansen C: Prevention and treatment of osteoporosis: a review of current modalities. Bone 13, Suppl 1, S35-S39 (1992)
2. Raisz LG: The osteoporosis revolution. Ann Intern Med 126, 458-462 (1997)
3. Stewart AF: PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19, 303-306 (1996)
4. Jee WS and Ma YF: The in vivo anabolic actions of prostaglandins in bone. Bone 21, 297-304 (1997)
5. Narumiya S: Prostanoid receptors. Structure, function, and distribution. Ann NY Acad Sci 744, 126-138 (1994)
6. Whitfleld JF and Morley P: Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Trends Pharmacol Sci 16, 382-386 (1995)
7. Teixeira MM, Gristwood RW, Cooper N and Hellewell PG: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 18, 164-171 (1997)
8. Beavo JA and Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11, 150-155 (1990)
9. Miyamoto K, Kurita M, Sakai R, Sanae F, Wakusawa S and Takagi K: Cyclic nucleotide phosphodiesterase isoenzymes in guinea-pig tracheal muscle and bronchorelaxation by alkylxanthines. Biochem Pharmacol 48, 1219-1223 (1994)
10. Miyamoto K, Waki Y, Horita T, Kasugai S and Ohya K: Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 54, 613-617 (1997)
11. Sakai R, Konno K, Yamamoto Y, Sanae F, Takagi K, Hasegawa T, Iwasaki N, Kakiuchi M, Kato H and Miyamoto K: Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem 35, 4039-4044 (1992)
12. Marivet MC, Bourguignon JJ, Lugnier C, Mann A, Stoclet JC and Wermuth CG: Inhibition of cyclic adenosine 3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem 32, 1450-1457 (1989)
13. Maniatopoulos C, Sodek J and Melcher AH: Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 254, 317-330 (1988)
14. Kasugai S, Oida S, Iimura T, Arai N, Takeda K, Ohya K and Sasaki S: Expression of prostaglandin E receptor subtypes in bone: expression of EP2 in bone development. Bone 17, 1-4 (1995)
15. Kondo H, Ohyama T, Ohya K and Kasugai S: Temporal changes of mRNA expression of matrix proteins and parathyroid hormone and parathyroid hormone-related protein (PTH/PTHrp) receptor in bone development. J Bone Miner Res 12, 2089-2097 (1997)
16. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A and Suda T: Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122, 1373-1382 (1988)
17. Soekanto A, Ohya K and Ogura H: The effect of sodium salicylate on the osteoclast-like cell formation and bone resorption in a mouse bone marrow culture. Calcif Tissue Int 54, 290-295 (1994)
18. Ozawa S and Kasugai S: Evaluation of implant materials (hydroxyapatite, glass-ceramics, titanium) in rat bone marrow stromal cell culture. Biomaterials 17, 23-29 (1996)
19. Laczka-Osyczka A, Laczca M, Kasugai S and Ohya H: Behavior of bone marrow cells cultured on three different coatings of gel-derived bioactive glass-ceramics at early stage of differentiation. J Biomed Mater Res 42, 433-442 (1998)
20. 2 effects on mineralized-tissue formation in vitro depend on the cell stage of osteoblastic lineage. J Bone Miner Res 10, Suppl 1, S420 (1995)
21. Kondo H, Kasugai S, Ozawa S, Mukohyama H, Ohya K and Ohyama T: The effects of parathyroid hormone (PTH) on mineralized tissue formation in rat bone marrow cell culture. J Bone Miner Res 10, Suppl 1, S420 (1995)
22. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW and Torphy TJ: Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 270, 250-259 (1994)
23. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG and Beavo JA: Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 29, 506-514 (1986)
24. Burns F, Rodger IW and Pyne NJ: The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea pig lung. Biochem J 283, 487-491 (1992)
25. Kasugai S, Miyamoto K, Waki Y, Mukohyama H, Kondo H and Ohya K: A phosphodiesterase 4 inhibitor, rolipram, increases osteoprogenitors in rat bone marrow. J Bone Miner Res 12, Suppl 1, S476 (1997)
26. Friedenstein AJ, Chailakhyan RK and Gerasimov UV: Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 20, 263-272 (1987)
27. Waki Y, Miyamoto K, Kasugai S and Ohya K: Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production. Jpn J Cancer Res 86, 470-476 (1995)
28. Waki Y, Nomura M, Kasugai S, Ohya K and Miyamoto K: Walker 256/S carcinosarcoma causes osteoporosis-like changes through ectopical secretion of luteinizing hormone-releasing hormone. Cancer Res 59, 1219-1224 (1999)
29. 2, interleukin 1-alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro. Endocrinology 139, 3157-3164 (1998)
30. Pfeilschifter J, Chenu C, Bird A, Mundy GR and Roodman GD: Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res 4, 113-118 (1989)
31. Kitajima I, Nakajima T, Imamura T, Takasaki I, Kawahara K, Okano T, Tokioka T, Soejima Y, Abeyama K and Maruyama I: Induction of apoptosis in murine clonal osteoblasts expressed by human T-cell leukemia virus type I tax by NF-kappa B and TNF-alpha. J Bone Miner Res 11, 200-210 (1996)
32. Hill PA, Tumber A and Meikle MC: Multiple extracellular signals promote osteoblast survival and apoptosis. Endocrinology 138, 3849-3858 (1997)
33. Jilka RL, Weinstein RS, Bellido T, Parfitt AM and Manolagas SC: Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13, 793-802 (1998)
34. Yeh CK and Rodan GA: Tensile forces enhance prostaglandin E synthesis in osteoblastic cells grown on collagen ribbons. Calcif Tissue Int 36, S67-S71 (1984)
35. Turner CH, Takano Y, Owan I and Murrell GA: Nitric oxide inhibitor L-NAME suppresses mechanically induced bone formation in rats. Am J Physiol 270, E634-E639 (1996)
36. 2 in osteoblasts by wall-shear stress but not mechanical strain. Am J Physiol 273, E751-E758 (1997)
37. Sakai A, Nakamura T, Tsurukami H, Okazaki R, Nishida S, Tanaka Y, Norimura T and Suzuki K: Bone marrow capacity for bone cells and trabecular bone turnover in immobilized tibia after sciatic neurectomy in mice. Bone 18, 479-486 (1996)
38. Kalu DN: The ovariectomized rat model of postmenopausal boneless. Bone Miner 15, 175-191 (1991)
39. Pacifici R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11, 1043-1051 (1996)
40. Romas E and Martin TJ: Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 7, S47-S53 (1997)
41. Siegmund B, Eigler A, Moeller J, Greten TF, Hartmann G and Endres S: Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. Eur J Pharmacol 321, 231-239 (1997)
42. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Tanaka H and Nagai H: Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononudear cells. Gen Pharmacol 29, 633-638 (1997)
43. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M and Strassmann G: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol 155, 4909-4916 (1995)